Rain Therapeutics Inc

RAIN | $1.21 0.0% 3.7M

(0.0% 1d) (0.0% 1m) (-81.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (979.26% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 33,371,736
https://www.rainthera.com
Sec Filling | Patents | n/a employees

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

cancer t-cell genetic ceiling

add to watch list Paper trade email alert is off

PharmaCyte Biotech Inc

PMCB | $2.22 1.4% 1.6K

Manufacturing

(0.0% 1d) (-14.1% 1m) (-28.8% 1y) (0.0% 2d) (-4.1% 3d) (0.5% 7d) (-79.56% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 18,766,539
https://www.pharmacytebiotech.com
Sec Filling | Patents | 4 employees

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.

diabetic diabetes msa ceiling cancer genetic t-cell

add to watch list Paper trade email alert is off

Alaunos Therapeutics Inc

TCRT 4 | $1.18 8.26% 7.63% 46K

Manufacturing

(0.0% 1d) (-37.2% 1m) (136.8% 1y) (0.0% 2d) (10.1% 3d) (7.1% 7d) (22.22% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 18,894,725
https://www.ziopharm.com
Sec Filling | Patents | 105 employees

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

ceiling cancer genetic gene therapies t-cell

add to watch list Paper trade email alert is off